Dr. Davendra P. Sohal
Claim this profileUniversity of Cincinnati Medical Center
Studies Cancer
Studies Colorectal Cancer
23 reported clinical trials
44 drugs studied
About Davendra P. Sohal
Education:
- Earned an MD (Doctor of Medicine).
- Obtained an MPH (Master of Public Health).
Experience:
- Serves as Associate Director for Clinical Research at the University of Cincinnati Cancer Center.
- Completed a Fellowship in Hematology and Oncology at the University of Pennsylvania.
- Held the position of Chief Resident in Internal Medicine at Jacobi Medical Center, Albert Einstein College of Medicine.
- Acts as a professor and hosted the Second Annual 'Updates on Hematology & Oncology Conference' at the University of Cincinnati Medical Center.
Area of expertise
1Cancer
Stage IV
Stage III
TSC1 positive
2Colorectal Cancer
Stage IV
PIK3CA positive
MSI-low positive
Affiliated Hospitals
Clinical Trials Davendra P. Sohal is currently running
TAC01-CLDN18.2 Engineered T-cells
for Cancer
TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.
Recruiting1 award Phase 1 & 2
TAK-676 + Pembrolizumab
for Metastatic Cancer
This trial is testing a new drug called dazostinag, alone and with another drug called pembrolizumab, to treat people with advanced solid tumors. It focuses on patients with specific types of head and neck cancer and colorectal cancer who have few other treatment options. The goal is to find a safe dose and see if the combination can help the immune system fight the cancer more effectively.
Recruiting2 awards Phase 1 & 210 criteria
More about Davendra P. Sohal
Clinical Trial Related4 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Davendra P. Sohal has experience with
- Gemcitabine
- Capecitabine
- Placebo
- RP3
- Atezolizumab
- Bevacizumab
Breakdown of trials Davendra P. Sohal has run
Colorectal Cancer
Pancreatic Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Davendra P. Sohal specialize in?
Davendra P. Sohal focuses on Cancer and Colorectal Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Davendra P. Sohal currently recruiting for clinical trials?
Yes, Davendra P. Sohal is currently recruiting for 11 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Davendra P. Sohal has studied deeply?
Yes, Davendra P. Sohal has studied treatments such as Gemcitabine, Capecitabine, Placebo.
What is the best way to schedule an appointment with Davendra P. Sohal?
Apply for one of the trials that Davendra P. Sohal is conducting.
What is the office address of Davendra P. Sohal?
The office of Davendra P. Sohal is located at: University of Cincinnati Medical Center, Cincinnati, Ohio 45267 United States. This is the address for their practice at the University of Cincinnati Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.